


Adverse Event Databank Open to Members



The AAE's databank to collect adverse event reports is now open at www.aae.org/adverseevents.

The AAE requests that its members report to the databank any adverse event involving N-2, N-2 Universal, RC-2B or RC-2B White, or Endocal 10 (formerly known as Biocalex 6-9) when used in endodontic treatment.

The Food and Drug Administration defines an adverse event as "any unfavorable and unintended sign, symptom or disease

temporally associated with the use of a medicinal product, whether or not considered related to the product."

The Association plans to use the databank to refine its own policy on these products, to assist government agencies concerned with endodontic treatment issues, and to promote relevant scientific studies, education and research. The Association

does not intend to make judgments about the reported cases, however, the AAE may transmit the information that is received to officials who are responsible for protecting the dental health of the public, as well as to researchers and educators who are studying the safety of the products.

Members should use their best professional judgment and a scientific approach in determining whether a patient who has been treated with one of these products has experienced an adverse event.

In an effort to maintain the privacy of patients and to comply with the regulations under the Health Insurance Portability and Accountability Act, the AAE asks that the name of the patient not be furnished. Please remove any information that would permit identification unless the patient has provided written authorization to allow his/her identity to be shared. However, do maintain the identifying information in your records.

If you have any questions, please contact Elizabeth A. Lalasz, policy coordinator, at 800/872-3636 (North America) or 312/266-7255 (International), ext. 3015, or send an e-mail to elalasz@aae.org.